Comparison of nanosuspensions and hydroxypropyl-β-cyclodextrin complex of melarsoprol: Pharmacokinetics and tissue distribution in mice

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 2, 2008, Pages 649-656

  Ben Zirar, Siham ^a   Astier, Alain ^a   Muchow, Marc ^a   Gibaud, Stéphane ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Arsenic; Cyclodextrin; Leukemia; Melarsoprol; Nanosuspensions

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTILEUKEMIC AGENT; ARSENIC; MELARSOPROL; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW; BRAIN; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DISTRIBUTION VOLUME; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LD 50; LEUKEMIA; MOUSE; NANOSUSPENSION; NONHUMAN; TISSUE DISTRIBUTION; TREATMENT PLANNING; TRYPANOSOMIASIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; FEMALE; HUMANS; K562 CELLS; LETHAL DOSE 50; MELARSOPROL; MICE; NANOPARTICLES; SUSPENSIONS; TISSUE DISTRIBUTION; TRYPANOCIDAL AGENTS; U937 CELLS;

EID: 52949128719     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.05.012     Document Type: Article

References (47)

1. Kennedy P.G. Human African trypanosomiasis-neurological aspects. J. Neurol. 253 (2006) 411-416
2. Pepin J., Milord F., Guern C., Mpia B., Ethier L., and Mansinsa D. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet 1 (1989) 1246-1250
3. E.A.H. Friedheim, Propylene glycol solution of arsenic medicaments, U.S. Patent 2,593,434 (1952).
4. Jennings F.W., Urquhart G.M., Murray P.K., and Miller B.M. The use of 2-substituted 5-nitroimidazoles in the treatment of chronic murine Trypanosoma brucei infections with central nervous system involvement. Z. Parasitenkd. 70 (1984) 691-697
5. Soignet S.L., Tong W.P., Hirschfeld S., and Warrell Jr. R.P. Clinical study of an organic arsenical melarsoprol in patients with advanced leukemia. Cancer Chemother. Pharmacol. 44 (1999) 417-421
6. A. Astier, S. Gibaud, Use of organoarsenic or organoantimony derivatives for their anticancer activities, WO Patent 2005034935 (2005).
7. Gibaud S., Alfonsi R., Mutzenhardt P., Fries I., and Astier A. (2-phenyl-[1,3,2]dithiarsolan-4-yl)-methanol derivatives show in vitro antileukemic activity. J. Organometallic Chem. 691 (2006) 1081-1084
8. Gibaud S., and Astier A. Organoarsenicals derived from 2-phenyl-[1,3,2]dithiarsolan-4-yl)-methanol (AsIII) with antileukaemic properties: from trypanosomicides to anticancer drugs. Ann. Pharm. Fr. 65 (2007) 162-168
9. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
10. Bittner B., and Mountfield R.J. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr. Opin. Drug Discov. Dev. 5 (2002) 59-71
11. Szejtli J. Cyclodextrin technology (1988), Kluwer Academic Publishers, Dordrecht, Netherlands
12. Gibaud S., Ben Zirar S., Mutzenhardt P., Fries I., and Astier A. Melarsoprol-cyclodextrins inclusion complexes. Int. J. Pharm. 306 (2005) 107-121
13. Wempe M.F., Wacher V.J., Ruble K.M., Ramsey M.G., Edgar K.J., Buchanan N.L., and Buchanan C.M. Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. Int. J. Pharm. 346 (2008) 25-37
14. Buchanan C.M., Buchanan N.L., Edgar K.J., Little J.L., Ramsey M.G., Ruble K.M., Wacher V.J., and Wempe M.F. Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-beta-cyclodextrin formulations. Biomacromolecules 9 (2008) 305-313
15. Grosse P.Y., Bressolle F., Rouanet P., Joulia J.M., and Pinguet F. Methyl-beta-cyclodextrin and doxorubicin pharmacokinetics and tissue concentrations following bolus injection of these drugs alone or together in the rabbit. Int. J. Pharm. 180 (1999) 215-223
16. Grislain L., Couvreur P., Lenaerts V., Roland M., Deprez-Decampeneere D., and Speiser P. Pharmacokinetics and distribution of biodegradable drug-carriers. Int. J. Pharm. 15 (1983) 335-345
17. Gibaud S., Weingarten C., Andreux J.P., and Couvreur P. Ciblage de la moelle osseuse à l'aide de nanoparticules de polyalkylcyanoacrylate. Ann. Pharm. Fr. 57 (1999) 324-331
18. Gibaud S., Demoy M., Andreux J.P., Weingarten C., Gouritin B., and Couvreur P. Cells involved in the capture of nanoparticles in hematopoietic organs. J. Pharm. Sci. 85 (1996) 944-950
19. Gibaud S., Andreux J.P., Weingarten C., Renard M., and Couvreur P. Increased bone marrow toxicity of doxorubicin bound to nanoparticles. Eur. J. Cancer 6 (1994) 820-826
20. Olivier J.C. Drug transport to brain with targeted nanoparticles. NeuroRx 2 (2005) 108-119
21. E.A.H. Friedheim, Substituted [1,3,5,-triazinyl-(6)]-aminophenyl-arsonic acids and process for manufacture of same, U.S. Patent 2,295,574 (1942).
22. E.A.H. Friedheim, Triazine organometallic compounds and process for preparing same, U.S. Patent 2,659,723 (1953).
23. R.H. Müller, R. Becker, B. Kruss, K. Peters, Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution, U.S. Patent 5,858,410 (1999).
24. Hansen M.B., Nielsen S.E., and Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119 (1989) 203-210
25. Elliot S.C., and Loper B.R. Improved absorption tube for arsenic determinations. Anal. Chem. 46 (1974) 2256-2257
26. Cristau B., and Placidi M. Routes and kinetics of arsenic elimination in rats after administration of organoarsenic drugs. IV. Biliary excretion of melarsoprol, melarsonyl and related compounds. Med. Trop. 32 (1972) 477-482
27. Burri C., Baltz T., Giroud C., Doua F., Welker H.A., and Brun R. Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy 39 (1993) 225-234
28. Ben Zirar S., Gibaud S., Camut A., and Astier A. Pharmacokinetics and tissue distribution of the antileukemic organoarsenicals arsthinol and melarsoprol in mice. J. Organometallic Chem. 692 (2007) 1348-1352
29. Keiser J., and Burri C. Physico-chemical properties of the trypanocidal drug melarsoprol. Acta Trop. 74 (2000) 101-104
30. Hiskey C.F., and Cantwell F.F. Ultraviolet spectrum correlations with the conjugate acid-base species of acetarsone and arsthinol. J. Pharm. Sci. 57 (1968) 2105-2111
31. Fairlamb A.H., Henderson G.B., and Cerami A. Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc. Natl. Acad. Sci. USA 86 (1989) 2607-2611
32. Cunningham M.L., Zvelebil M.J., and Fairlamb A.H. Mechanism of inhibition of trypanothione reductase and glutathione reductase by trivalent organic arsenicals. Eur. J. Biochem. 221 (1994) 285-295
33. Akao Y., Mizoguchi H., Kojima S., Naoe T., Ohishi N., and Yagi K. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br. J. Haematol. 102 (1998) 1055-1060
34. Gherardi R.K., Chariot P., Vanderstigel M., Malapert D., Verroust J., Astier A., Brun-Buisson C., and Schaeffer A. Organic arsenic-induced guillain-barre-like syndrome due to melarsoprol: a clinical, electrophysiological, and pathological study, Muscle Nerve 13 (1990) 637-645
35. Ain-Ai A., and Gupta P.K. Effect of arginine hydrochloride and hydroxypropyl cellulose as stabilizers on the physical stability of high drug loading nanosuspensions of a poorly soluble compound. Int. J. Pharm. 351 (2008) 282-288
36. Berger B.J., and Fairlamb A.H. Properties of melarsamine hydrochloride (Cymelarsan) in aqueous solution. Antimicrob. Agents Chemother. 38 (1994) 1298-1302
37. Ericsson O., Schweda E.K., Bronner U., Rombo L., Friden M., and Gustafsson L.L. Determination of melarsoprol in biological fluids by high-performance liquid chromatography and characterisation of two stereoisomers by nuclear magnetic resonance spectroscopy. J. Chromatogr. B 690 (1997) 243-251
38. Porter C.J., Moghimi S.M., Illum L., and Davis S.S. The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett. 305 (1992) 62-66
39. Moghimi S.M., Hunter A.C., and Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53 (2001) 283-318
40. Kreuter J., Alyautdin R.N., Kharkevich D.A., and Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674 (1995) 171-174
41. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47 (2001) 65-81
42. Olivier J.C., Fenart L., Chauvet R., Pariat C., Cecchelli R., and Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res. 16 (1999) 1836-1842
43. Kreuter J., Petrov V.E., Kharkevich D.A., and Alyautdin R.N. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J. Control. Release 49 (1997) 81-87
44. Xi-Xiao Y., Jan-Hai C., Shi-Ting L., Dan G., and Xv-Xin Z. Polybutylcyanoacrylate nanoparticles as a carrier for mitomycin C in rabbits bearing VX2-liver tumor. Regul. Toxicol. Pharmacol. 46 (2006) 211-217
45. Frijlink H.W., Franssen E.J., Eissens A.C., Oosting R., Lerk C.F., and Meijer D.K. The effects of cyclodextrins on the disposition of intravenously injected drugs in the rat. Pharm. Res. 8 (1991) 380-384
46. Stella V.J., Rao V.M., Zannou E.A., and Zia V.V. Mechanisms of drug release from cyclodextrin complexes. Adv. Drug Deliv. Rev. 36 (1999) 3-16
47. Koshiuka K., Elstner E., Williamson E., Said J.W., Tada Y., and Koeffler H.P. Novel therapeutic approach: organic arsenical melarsoprol alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo. Br. J. Cancer 82 (2000) 452-458